Innovation and greater probability of success in drug discovery and development -- from target to biomarkers.

作者：

DOI: 10.1016/J.COPBIO.2005.10.014

关键词:

摘要:

nih.gov 本地加速

sciencedirect.com 本地加速

elsevier.com 本地加速

sci-hub.se PDF 下载加速

参考文章(6)

Ismail Kola, John Landis, Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery. ,vol. 3, pp. 711- 716 ,(2004) , 10.1038/NRD1470

E SCHADT, Exploiting naturally occurring DNA variation and molecular profiling data to dissect disease and drug response traits. Current Opinion in Biotechnology. ,vol. 16, pp. 647- 654 ,(2005) , 10.1016/J.COPBIO.2005.10.005

G MAKARA, J ATHANASOPOULOS, Improving success rates for lead generation using affinity binding technologies. Current Opinion in Biotechnology. ,vol. 16, pp. 666- 673 ,(2005) , 10.1016/J.COPBIO.2005.10.007

R PHILLIPS, A SACHS, Skin biopsies for the measurement of clinical pharmacodynamic biomarkers. Current Opinion in Biotechnology. ,vol. 16, pp. 687- 690 ,(2005) , 10.1016/J.COPBIO.2005.10.010

H MOMOTA, E HOLLAND, Bioluminescence technology for imaging cell proliferation. Current Opinion in Biotechnology. ,vol. 16, pp. 681- 686 ,(2005) , 10.1016/J.COPBIO.2005.10.012

V LABHASETWAR, Nanotechnology for drug and gene therapy: the importance of understanding molecular mechanisms of delivery. Current Opinion in Biotechnology. ,vol. 16, pp. 674- 680 ,(2005) , 10.1016/J.COPBIO.2005.10.009